Showing 4,461 - 4,480 results of 44,759 for search '(( 5 ((ng decrease) OR (mean decrease)) ) OR ( 50 ((nn decrease) OR (a decrease)) ))', query time: 0.83s Refine Results
  1. 4461

    Bcl-xL protein levels were decreased in response to siRNA transfection in A549, SK-LU1 and NP-69 cells. by Norahayu Othman (495150)

    Published 2013
    “…<p>(<b>A</b>) Western blot indicating a significant decrease in Bcl-xL protein levels in comparison to non-transfected cells 48 h post-transfection. …”
  2. 4462
  3. 4463
  4. 4464

    (A) The proportion of fast MyHC myotubes is decreased in Igf-2 deficient mice (maternal disomy Chromosome 7 - MatDi) at E14 by Deborah Merrick (54928)

    Published 2011
    “…<p><b>Copyright information:</b></p><p>Taken from "A role for Insulin-like growth factor 2 in specification of the fast skeletal muscle fibre"</p><p>http://www.biomedcentral.com/1471-213X/7/65</p><p>BMC Developmental Biology 2007;7():65-65.…”
  5. 4465
  6. 4466

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  7. 4467

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  8. 4468

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  9. 4469

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  10. 4470

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  11. 4471

    Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

    Published 2022
    “…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
  12. 4472
  13. 4473
  14. 4474
  15. 4475
  16. 4476
  17. 4477
  18. 4478
  19. 4479
  20. 4480